Trellus Health plc

("Trellus Health" or the "Company")

Posting of Annual Report & Accounts

and
Notice of Annual General Meeting

LONDON, UK. AND NEW YORK, U.S. (20 May 2024). Trellus Health plc (AIM: TRLS), a health services company delivering innovative, scientifically validated programs and technologies designed to facilitate the management of chronic conditions, improve health outcomes and lower the costs of care, confirms that the Annual Report and Accounts for the year ended 31 December 2023 ("2023 Annual Report") and the Notice of the 2023 Annual General Meeting ("AGM") have now been published on the Company's website here.

The 2023 Annual Report, the Notice of AGM and details for voting by proxy will be posted to shareholders today, on 20 May 2024.

The AGM will be held at 12pm on 14 June 2024 at the offices of Shoosmiths, at 1 Bow Churchyard, London EC4M 9DQ, and will consider the Resolutions set out in the Notice of AGM.

Proxy voting

Shareholders will not receive a hard copy form of proxy for the 2024 AGM in the post. Instead, you will be able to vote electronically using the Link Investor Centre app or at https://investorcentre.linkgroup.co.uk/Login/Login. Proxy votes must be received no later than 12pm on 12 June 2024.

Shareholders may request a hard copy form of proxy directly from the Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.

For further information please contact:

About Trellus Health plc (www.trellushealth.com)

Trellus Health (AIM: TRLS) is a health services company providing value-based innovative solutions and services for chronic condition management that prioritises improved outcomes and member experiences while managing costs of care.

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate™, a whole-person technology-enhanced experience that meets each individual's unique needs and empowers them to master their physical and emotional health. Trellus Elevate's™ clinically proven solutions result in relieving disease burden, building self-management skills and promoting positive health behaviours that improve outcomes and enables thriving in the face of a chronic condition.

The Company's proven whole person approach recognises the interconnectedness of various aspects of a person's life and aims to address the whole spectrum of factors that influence behaviour, to promote comprehensive well-being and human flourishing in a way that aligns with value-based care. Trellus Health's approach enables better health outcomes in a member-centric, personalised and comprehensive holistic solution.

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

The Company is initially focusing on chronic costly GI conditions that have high mental health burden, such as inflammatory bowel disease ("IBD") which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis. Given the common emotional and mental health struggles often experienced by individuals suffering from a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

The Trellus Elevate™ program incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than seven years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers and health systems. Patients with IBD managed with the proprietary resilience methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following starting the program which is a major indicator of improved health outcomes^1.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit: www.trellushealth.com

¹ Source: https://www.sciencedirect.com/science/article/pii/S1542356521012258